Advanced colon cancer with bladder metastasis complicated by disseminated intravascular coagulation: a case report

doi:10.16352/j.issn.1001-6325.2025.12.1648

Abstract

Abstract: Objective To investigate the management strategies for disseminated intravascular coagulation (DIC) secondary to advanced malignancies. Methods Clinical data of an elderly male with advanced colon cancer, multiple bladder/pelvic wall metastases, and secondary DIC was collected and analysed. Diagnostic and therapeutic processes were systematically evaluated. Results The patient successfully underwent surgery to relieve urinary tract obstruction after transfusion support. Despite subsequent correction of coagulopathy with supportive care and anticoagulation, the prognosis remained poor due to tumor progression and DIC decompensation. Conclusions The management of malignancy-complicated DIC requires dynamic assessment of coagulation status. Temperate anticoagulation might aid in DIC control even in the presence of bleeding risk.

Key words: colon cancer, bladder metastasis, disseminated intravascular coagulation

CLC Number:

LI Siyuan, DONG Jie. Advanced colon cancer with bladder metastasis complicated by disseminated intravascular coagulation: a case report[J]. Basic & Clinical Medicine, 2025, 45(12): 1648-1652.

References

[1] Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies[J]. Clin Appl Thromb Hemost, 2018,24(9_suppl): 8S-28S. doi: 10.1177/1076029618806424.
[2] Levi M, Scully M. How I treat disseminated intravascular coagulation[J]. Blood, 2018,131:845-854. doi: 10.1182/blood-2017-10-804096.
[3] Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism[J]. Nat Rev Dis Primers, 2022,8:11. doi: 10.1038/s41572-022-00336-y.
[4] Seki Y, Okamoto K, Ikezoe T, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities[J]. Int J Hematol, 2025,121:622-632. doi: 10.1007/s12185-024-03912-y.
[5] van Bunderen CC, de Weger VA, Griffioen-Keijzer A. Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature[J]. Neth J Med, 2014,72:186-189.
[6] Mizota A, Shitara K, Kondo C, et al. A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab[J]. Int J Clin Oncol, 2011,16:766-769. doi: 10.1007/s10147-011-0242-2.
[7] Kato H, Kohata K, Yamamoto J, et al. Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer[J]. Int J Hematol, 2010, 91:328-330. doi: 10.1007/s12185-010-0491-2.
[8] Misawa R, Kobayashi M, Ito M, et al. Primary colonic signet ring cell carcinoma presenting carcinocythemia: an autopsy case[J]. Case Rep Gastroenterol, 2008, 2:301-307. doi: 10.1159/000155146.
[9] Huang WT, Chang KC, Shan YS, et al. Successful initial treatment with weekly 24-hour infusion of 5-fluorouracil and leucovorin in a rectal cancer patient with acute disseminated intravascular coagulation[J]. Hepatogastroenterology, 2005,52:1436-1439.
[10] Yoshioka K, Shimizu H, Yokoo S, et al. Disseminated carcinomatosis of bone marrow from submucosal carcinoma in adenoma of the rectum[J]. Intern Med, 1992,31:1056-1059. doi: 10.2169/internalmedicine.31.1056.

[1]	SUN Ting, ZOU Teng, YANG Yisong, LIU Shuangping, REN Xin, WANG Dan. Inhibitory effect of β-elemonic acid on proliferation and invasion of colon cancer cell lines [J]. Basic & Clinical Medicine, 2025, 45(6): 748-754.
[2]	HAN Wei, PAN Wei, ZHANG Man, GAO Xiangyu, KANG Xinkai, ZHU Zhibo, LIU Ruiting. Scoparone inhibits proliferation and invasion of colon cancer cell line HCT116 [J]. Basic & Clinical Medicine, 2025, 45(11): 1429-1437.
[3]	YAO Anjun, CHEN Lingzi, JIN Huixian. Docosahexaenoic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2024, 44(8): 1107-1112.
[4]	HE Yangzhige, JIANG Xu, ZHANG Zhiwen, GONG Yiyi. PTGS2 affects prognosis of colon cancer patients through regulation of cell proliferation and antioxidant capacity [J]. Basic & Clinical Medicine, 2024, 44(11): 1522-1529.
[5]	FENG Naxin, WANG Peng, HE Mingxuan, LIU Jinyan. Pachymic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2023, 43(11): 1673-1679.
[6]	YAN Wen, LI Nan, GU Tongnan, KONG Xiangzhao. Screening and verification of key genes for colon cancer based on GEO database [J]. Basic & Clinical Medicine, 2023, 43(11): 1685-1692.
[7]	GAO Hong-ting, HUANG Yu-qing, YANG Li-xing, MA Rui, WANG Yu-cheng, JU Rui, GUO Lei. Carboxyamidotriazole enhances the effects of mouse spleen lymphocytes on promoting the apoptosis of colon cancer cell lines MC38 and C26 [J]. Basic & Clinical Medicine, 2021, 41(6): 805-810.
[8]	XIN Yu, HE Long-mei, YANG Hong, LYU Hong, TAN Bei, WANG Hong-ying, QIAN Jia-ming. 1α,25-Dihydroxyvitamin D₃ inhibits β-catenin transcriptional activity in human colon cancer cell line SW480 [J]. Basic & Clinical Medicine, 2020, 40(9): 1169-1174.
[9]	TIAN Chun-yang, LIU Xiao-zheng, FAN Jun-chao. Oxaliplatin combined with daunorubicin induces apoptosis of colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2020, 40(3): 310-314.
[10]	SHI Guang, NING Na, HOU Xiao-hong, SUN Cong, YUAN Yuan, WANG Li, WANG Xiao-hui. Rev-erb agonist SR9009 inhibits the proliferation of human colon cancer cell line HCT116 through reducing autophagy [J]. Basic & Clinical Medicine, 2020, 40(11): 1494-1499.
[11]	. Effect of CoCl2 on CacyBP/SIP nuclear translocation of cell lines of colon carcinoma [J]. Basic & Clinical Medicine, 2012, 32(11): 1312-1317.
[12]	Xue-hu WANG; Zhong-xue FU; Wei SHEN; Xing-ye WU. VEGF-induced Expression of Survivin in Differernt Types of Cells [J]. Basic & Clinical Medicine, 2009, 29(12): 1239-1243.
[13]	Yang LU; Bo LIU; Jun-xu REN; Jing-fang WU; Po ZHAO; Gang XUE. Clinicopathologic and prognostic study on 404 cases of colon cancer [J]. Basic & Clinical Medicine, 2008, 28(5): 507-510.